A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

E. Hamilton, Maila Dayane Capuchinho de Oliveira, Nicholas C. Turner, J. García-Corbacho, Cristina Hernándo, Eva Ciruelos, Peter Kabos, Manuel Ruíz‐Borrego, Anne Armstrong, Mehul Patel, Christos Vaklavas, Chris Twelves, Valentina Boni, Jason Incorvati, Tim Brier, L. Gibbons, Teresa Klinowska, Justin P.O. Lindemann, Christopher J. Morrow, Anne-Marie Sykes, Richard D. Baird